

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

February 14, 2018

To,

BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code - 539730

Subject: Newspaper Advertisement of the Financial Statements for Quarter ended December 2017


Dear Sir / Madam,

In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for Quarter & Nine Months ended December 2017; as approved by the Board in its Meeting held on Monday, February 12, 2018; published in Navshakti & Free-press Journal on February 13, 2018.

Kindly take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited



DIRECTOR



Encl. - A/a

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031, (INDIA)

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone: 91-22-4031 8111 Fax: 91-22-4031 8133 E-mail: business@fredungroup.com Web: www.fredungroup.com





FREDUN PHARMACEUTICALS LTD.

CIN : L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031

Phone Number: +91 22 4031 8111 Fax: +91 22 4031 8133

Email: business@fredungroup.com | Website: www.fredungroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2017

(Rs. in Lacs)

Sr. No.	Particulars	Quarter Ended		Year to Date	Year ended
		Dec. 2017 (Unaudited)	Dec. 2016 (Unaudited)	Dec. 2017 (Unaudited)	March 2017 (Audited)
1.	Total Income from Operations	1388.41	1389.07	3868.37	5861.00
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	20.65	14.05	116.32	224.98
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	20.44	14.05	116.04	222.59
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	20.44	14.05	101.04	142.74
5.	Total Comprehensive Income for the period * (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	20.44	14.05	101.04	142.74
6.	Equity Share Capital	294.72	237.45	294.72	237.45
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	238.55
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
	1. Basic:	0.69	0.59	3.43	6.01
	2. Diluted:	0.69	0.59	3.43	6.01

Note:

- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com
- The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.
- # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For Fredun Pharmaceuticals Limited

Sd/-

Fredun Medhora

Managing Director & Compliance Officer

Place : Mumbai

Date : February 12, 2018



Tue, 13 February 2018

paper.freepressjournal.in//c/26245272



FREDUN PHARMACEUTICALS LTD.

CIN : L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031

Phone Number: +91 22 4031 8111 Fax: +91 22 4031 8133

Email: business@fredungroup.com | Website: www.fredungroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2017

(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended		Year to Date	Year ended
		Dec. 2017 (Unaudited)	Dec. 2016 (Unaudited)	Dec. 2017 (Unaudited)	March 2017 (Audited)
1.	Total Income from Operations	1388.41	1389.07	3868.37	5861.00
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	20.65	14.05	116.32	224.98
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	20.44	14.05	116.04	222.59
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	20.44	14.05	101.04	142.74
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	20.44	14.05	101.04	142.74
6.	Equity Share Capital	294.72	237.45	294.72	237.45
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	238.55
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
	1. Basic:	0.69	0.59	3.43	6.01
	2. Diluted:	0.69	0.59	3.43	6.01

Note:

- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com
- The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.
- # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For Fredun Pharmaceuticals Limited

Sd/-

Fredun Medhora

Managing Director & Compliance Officer

Place : Mumbai

Date : February 12, 2018

REE PRESS
JOURNAL

Tue, 13 February 2018

epaper.freepressjournal.in//c/26240508